The FDA recently removed non-ambulatory Duchenne patients from the gene therapy's indication, which Sarepta hopes to have reinstated.
Doctors can use the test, developed by Endeavor Health in collaboration with GenomicMD, to direct more aggressive treatment ...
The British company's CAR T-cell therapy will now be available through the National Health Service in England and Wales.
With $1.6 million from CPRIT, investigators are testing an endogenous T-cell therapy that has certain advantages over CAR ...